Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 08, 2025 10:30 ET | Source: March Biosciences, Inc

March Biosciences Presents Positive Interim Clinical Data from Phase 2 Trial of MB-105 CD5 CAR-T Cell Therapy at ASH 2025 Annual Meeting

100% complete response rate achieved in primary cohort with acceptable safety profile in relapsed/refractory T-cell lymphoma patients HOUSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) -- March Biosciences...
December 03, 2025 08:00 ET | Source: March Biosciences, Inc

March Biosciences Announces Appointment of Gurpreet Ratra, Ph.D., as Chief Business Officer

Biotech veteran with over 25 years of business development, strategy and operational experience joins March Bio’s management team HOUSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March...
November 11, 2025 08:00 ET | Source: March Biosciences, Inc

March Biosciences Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for MB-105 in Relapsed/Refractory CD5-Positive T-Cell Lymphoma

HOUSTON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), a clinical stage biotechnology company developing cell therapies for hard-to-treat cancers, today announced that the U.S....
November 03, 2025 09:00 ET | Source: March Biosciences, Inc

March Biosciences Announces Oral Presentation of MB-105 Interim Phase 2 Clinical Data at American Society of Hematology Annual Meeting

HOUSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today...
April 22, 2025 08:00 ET | Source: March Biosciences, Inc

March Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of MB-105, First-in-Class CD5 CAR-T Cell Therapy for T-Cell Lymphoma

Novel CAR design selectively targets malignant cells for patients with relapsed/refractory CD5-positive hematological diseases HOUSTON, April 22, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March...
January 28, 2025 08:00 ET | Source: March Biosciences, Inc

March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma

Company prepares to advance to Phase 2 clinical trial in early 2025 HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an emerging clinical stage biotechnology company...
December 19, 2024 08:00 ET | Source: March Biosciences, Inc

March Biosciences Elects Peter Olagunju as Chair of Board of Directors

HOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today...
October 23, 2024 08:00 ET | Source: March Biosciences, Inc

March Biosciences Closes Oversubscribed $28.4 Million Series A Financing

Mission BioCapital and 4BIO Capital led the financing with significant participation from new and existing investors, raising over $51 million to dateFunds will support Phase 2 development of March...